Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Gaat THROMBO het nu waar maken in 2018
Volgen
Vorige week wat congres-hoop, weinig opwindends daar, eigenlijk helemaal niets, en dus vandaag de ontnuchtering. Weer een mini-hobbeltje.
De grootste vergissing die thrombogenics(CEO De Haes) ooit heeft gemaakt was het niet aanvaarden van een overnamebod. Met de koers van vandaag als gevolg.
Hier blijf je beter weg. Doodlopende straat! Nog enkel goed om de schijn hoog te houden en de kas te plunderen tot ze leeg is. Van de ene meeting naar de andere, steeds aanwezig, enkel de aankondiging van hun aanwezigheid en daarna niets meer. Oorverdovend stil!! Jammer voor de mensen die hier nog geld in hebben zitten. Neem je verlies en probeer je geluk elders. Succes!
9:40 cumulatief volume 186. Is ooit anders geweest
Stuiptrekking hier? Oxurion NV 2,72 0,16 6,25 % 16:18:01
nee, denk morgen resultaten
Oxurion NV Business Update – Q3 2019 Positive Results from Phase 1 evaluating THR-149 for DME Presented at major international Retina Conferences Patient Enrolment Completed for THR-687 Phase 1 study Data read out around year end 2019 Total Cash & Investments at €60.5 million as of September 30, 2019 Highlights Pipeline Positive data from Phase 1 study evaluating THR-149 (Plasma Kallikrein Inhibitor) for the treatment of DME were presented at major Retinal Conferences THR-149 is well-tolerated and safe with no dose-limiting toxicities or drug-related serious adverse events reported Rapid onset of action starting at Day 1 with increasing average improvement in Best Corrected Visual Acuity (BCVA) of up to 7.5 letters at Day 14 following a single injection of THR-149 Activity maintained up to 6.4 letters improvement at Day 90 following a single injection of THR-149 Patient enrolment completed in Phase 1 safety study evaluating THR-687 (pan RGD integrin antagonist) for the treatment of DME Data read out anticipated around year end of 2019 Financial Oxurion had cash, cash equivalents & investments of €60.5 million at the end of September 2019. This compares to €67.6 million at the end of June 2019. Leuven, Belgium, October 18, 2019 – 7.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, today issues its business and financial update for the nine month period ending September 30, 2019. Oxurion is continuing to progress the development of its innovative pipeline of drug candidates for diabetic eye disease, particularly Diabetic Macular Edema (DME). The Oxurion clinical development pipeline consists of novel products with different mostly VEGF independent modes of action, which, together potentially give the Company access to a significant share of the large and fast-growing diabetic eye disease market. Oxurion’s clinical pipeline comprises of: a potent plasma kallikrein inhibitor (THR-149) which completed a Phase 1 multicenter, dose escalation study for the treatment of DME. Positive data showed that THR-149 is well-tolerated and safe with no dose-limiting toxicities or drug-related serious adverse events reported. The data also showed very promising efficacy results in relation to BVCA. a small molecule pan-RGD integrin antagonist (THR-687) being developed to treat a broad range of patients with diabetic eye disease. Phase 1 study with THR-687 completed patient enrolment in September 2019. Topline results from the Phase 1 study are expected around year end of 2019. a human placental growth factor (PlGF) neutralizing monoclonal antibody (THR-317). Following 2018 reported positive topline data from a Phase 1 study evaluating THR-317 for DME in monotherapy, Oxurion recently reported mixed topline results from an exploratory Phase 2a study THR-317 in combination with ranibizumab (Lucentis®) for DME. Oxurion is also evaluating THR-317 in a small Phase 2a study in Idiopathic Macular Telangiectasia Type 1 (MacTel 1). Topline data from this study are expected for early 2020. At that moment, Oxurion will announce its final overall development plans with THR-317. Patrik De Haes, M.D., CEO of Oxurion, commented: “The positive topline results from a Phase 1 study evaluating THR-149, a potent plasma kallikrein inhibitor, showed that THR-149 delivers a rapid and sustained gain in BCVA. The study also confirmed THR-149 was well-tolerated and safe.” “We are pleased with the feedback from the ophthalmology community to these exciting new data, especially since they potentially create a path towards a new and unique VEGF-independent therapy for treatment of DME. We are preparing for a follow-up Phase 2 clinical trial that will evaluate multiple doses of THR-149. This important study is expected to start in the first half of 2020.” “We are also looking forward to reporting the topline data from our Phase 1 study with THR-687, a small molecule pan-RGD integrin antagonist for the treatment of DME around year end. Our current cash of €60.5 million will allow us to progress all of our ongoing and planned clinical and preclinical developments into 2021.” Diabetic Eye Disease - A Significant and Growing area of medical need Diabetic eye disease is caused by hyperglycemia (high blood glucose levels) associated with diabetes. If left unchecked hyperglycemia causes damage to the capillaries supplying blood, and hence oxygen, to the retina, the structure at the back of the eye responsible for vison. Diabetic retinopathy (DR) is a serious, sight-threatening disease and the leading cause of vision loss among working-age adults. DR progresses from mild, non-proliferative to more severe or even proliferative stages (PDR). PDR, the more advanced stage of diabetic eye disease happens when the retina starts growing new fragile blood vessels, which often bleed into the vitreous leading to loss of vision. It is estimated that there are 150 million diabetics with DR of which 50 million have vision threatening disease. Diabetic macular edema (DME) is a severe complication of DR. DME is an accumulation of fluid in the macula – the part of the retina that controls detailed vision - due to leaking blood vessels. DME represents an area of major unmet medical need. The current standard of care, anti-VEGFs, have shown to deliver sub-optimal results. More than 50% of patients have an unsatisfactory early visual response with anti-VEGF therapy, and in many cases, they fail to achieve a clinically meaningful visual improvement.
Oxurion Pipeline Update THR-149 – a plasma kallikrein inhibitor for treatment of DME Positive Phase 1 Results with THR-149 for the treatment of DME – Phase 2 program expected to start in H1 2020 THR-149 is a novel plasma kallikrein inhibitor being developed for the treatment of DME. THR-149 acts through inhibition of the Plasma Kallikrein-Kinin (PKaI-Kinin) system, which is considered a validated target for DME. The Phase 1 study showed that THR-149: is well-tolerated and safe. No dose-limiting toxicities nor drug-related serious adverse events were reported at any of the dosages evaluated in the study. delivered promising results in relation to efficacy, in particular changes to the patient’s Best Corrected Visual Acuity (BCVA). A rapid onset of action was observed from Day 1, with an increasing average improvement in BCVA of up to 7.5 letters at Day 14. Importantly, this activity was maintained with an average improvement in BCVA of 6.5 letters at Day 90 following a single injection of THR-149. Data from the Phase 1 study with THR-149 have been presented at a number of major Retina Conferences in Europe and the US: 19th Congress of European Society of Retina Specialists (EURETINA) in Paris (5 – 8 September), Retina Society Annual Meeting in London (11–15 September), and the American Academy of Ophthalmology Annual Meeting (AAO) in San Francisco (12 – 15 October). The Company is currently preparing to start a Phase 2 development program, which will evaluate multiple doses of THR-149 in patients with DME. This study is expected to start in early 2020. This novel drug candidate was generated using Bicycle Therapeutics’ Bicycles® technology platform. THR-687 – an integrin antagonist for treatment of DME Oxurion is developing THR-687, a novel pan-RGD integrin antagonist, to preserve vision of a broad range of patients with diabetic eye disease. This wide-ranging potential is based on the hypothesis that integrin inhibition can address many of the processes that result in the pathological angiogenesis and vascular leakage that cause diabetic eye disease. Oxurion is initially targeting THR-687 for the treatment of DME. In September, Oxurion completed recruitment of a Phase 1 multicenter, dose escalation study evaluating the safety of a single intravitreal injection of THR-687 for the treatment of patients with DME. Twelve patients were enrolled in the study. Initial results from this study are anticipated around year end 2019. THR-317 – a Humanized mAb Against Human PlGF for the treatment of DME THR-317 (anti-PlGF) is a recombinant humanized monoclonal antibody directed against the receptor-binding site of human placental growth factor (PlGF). THR-317 is being developed for the treatment of DME. In 2018, positive Phase 1 data demonstrated the potential of THR-317 for treatment of diabetic macular edema in monotherapy. Topline results from that study showed strong safety data as well as first indications of clinical activity and durability of effect. Following those positive results, the Company initiated a Phase 2a exploratory proof of concept study evaluating THR-317 in combination with ranibizumab (Lucentis®) for treatment of DME. In August 2019, the Company announced the topline results from an exploratory 70 patient Phase 2a study evaluating the efficacy and safety of intravitreal THR-317 administered in combination with ranibizumab (Lucentis®) a VEGF inhibitor, for the treatment of DME. The study showed that the combination did not produce an increase in BCVA in the overall population at Month 3. Certain improvement in mean BCVA at Month 3 could be observed with the combination therapy in 2 pre-specified subgroups of interest: o poor (or non) responders to prior anti-VEGF, and o patients with poor vision - baseline BCVA =65 letters Topline data confirmed that THR-317 in combination with ranibizumab is safe and well-tolerated. THR-317 clinical development plans in DME are currently under review. Phase 2 clinical study evaluating THR-317 for treatment of MacTel1 Oxurion is recruiting patients in a Phase 2 multi-center study evaluating the efficacy and safety of intravitreal THR-317 for the treatment of Macular Telangiectasia Type 1 (MacTel 1). MacTel 1 is a rare disease that affects the macula and can lead to vision loss. There is currently no effective treatment for MacTel 1. This Phase 2 study plans to enroll a maximum of 10 patients with macular edema caused by MacTel 1. Each patient will receive three 8mg intravitreal THR-317 injections over a period of 2 months. Efficacy and safety of the therapy will be assessed via functional and anatomic endpoints. Initial results from this clinical study are anticipated by early 2020. Financial Update As of September 30, 2019, Oxurion had €60.5 million in cash, cash equivalents and investments. This compares with €67.6 million as of the end of June 2019.
Is er toch ergens ene op het forum die kwartaalupdates als red flag beschouwt... waarschijnlijk terecht, als ik zie welke bedrijven eraan meedoen. 7M weg in het 3de kwartaal. Voor de rest is het blabla...
Uit de Tijd: 07:55 Oxurion verbrandde 7 miljoen in derde kwartaal De kaspositie van Oxurion was eind september geslonken tot 60,5 miljoen euro. Eind juni had het biofarmabedrijf nog 67,6 miljoen euro in kas. Het geld gaat vooral naar lopende onderzoeken. De pijplijn van Oxurion, dat innovatieve behandelingen voor oogproblemen bij diabetici probeert te ontwikkelen, omvat momenteel drie potentiële geneesmiddelen: THR-149 leverde in een fase 1-studie positieve resultaten op: een gezichtsverbetering (BCVA) tot 7,5 letters veertien dagen na een enkele injectie met het middel. De fase 1-resultaten van THR-687 worden rond het einde van het jaar verwacht. Het derde middel, THR-317, leverde in een onderzoek in combinatie met ranibizumab (Lucentis) ter behandeling van diabetisch maculair oedeem echter 'gemengde' resultaten op. Daarop kreeg het aandeel Oxurion zijn grootste pandoering ooit.
Het geld gaat, vooral, naar lopende onderzoeken schrijft De Tijd. Ik denk dat het meer gaat naar zakkenvullende bio-ingenieurs en snoepreisjes.
Cashburn is onder controle, een ander positief punt is de feedback van de oftalmologiegemeenschap, blijkbaar wordt oxurion nog serieus genomen. Vrees wel voor 687, te weinig informatie duidt meestal op onzekerheid over de molecule. Ik denk dat ze alles gaan zetten op 149 en hiervoor zo vlug mogelijk een partner willen aantrekken. Tot einde 2020 nog in leven, daarna ????
Zoals KBC zegt, zal veel afhangen van de resultaten van Kalvista. De ene zijn dood, is de andere zijn brood. Laat ons hopen voor de believers dat het brood voor oxurion zal zijn.
SISYPHUS schreef op 18 oktober 2019 13:05 :
Zoals KBC zegt, zal veel afhangen van de resultaten van Kalvista. De ene zijn dood, is de andere zijn brood. Laat ons hopen voor de believers dat het brood voor oxurion zal zijn.
Ik denk dat je het fout verstaat. Men moet hopen dat de Kalvista kvd001 resultaten goed zijn. Zoniet komt er twijfel over de plasma kalikrein inhibitors.
JdeFL schreef op 20 augustus 2019 20:43 :
Beetje houvast:
Het beurshuis Degroof Petercam wacht daar niet op en schrapte het project alvast uit zijn waarderingsmodel waardoor het koersdoel zakt van 4 naar 2,80 euro.
Van het koersdoel van 2,80 euro komt amper 0,80 euro van de pijplijn, en 2 euro van de cashpositie.
Beetje teruggebladerd. Sindsdien is jetrea opgegeven (waarde volgens KBC 0.08€) en heb je de cash burn van kwartaal 3 zo'n 0.18€. Mag er weer .25 af van wat ik totnogtoe redelijk vond, zijnde 2.55. 2.30 dus. Mijn mening, zonder enige garantie.
Tuurlijk Sanderus maar 149 moet beter zijn.
Dat hebben ze meer dan bewezen in hun fase 1 studie.
sanderus_1 schreef op 18 oktober 2019 17:59 :
Dat hebben ze meer dan bewezen in hun fase 1 studie.
Fase 1 studies geven geen bewijs; het is slechts een voorspel.
Bij fase 1 op gezonde vrijwilligers klopt dat. Bij 149 was dit bij patiënten met DME
Zitten nu erg dicht bij hun laagste koers van de laatste 5 jaar (2.51).
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee